JP2009529544A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529544A5
JP2009529544A5 JP2008558611A JP2008558611A JP2009529544A5 JP 2009529544 A5 JP2009529544 A5 JP 2009529544A5 JP 2008558611 A JP2008558611 A JP 2008558611A JP 2008558611 A JP2008558611 A JP 2008558611A JP 2009529544 A5 JP2009529544 A5 JP 2009529544A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
optionally substituted
substituents
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008558611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529544A (ja
JP5419468B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000428 external-priority patent/WO2007104162A1/en
Publication of JP2009529544A publication Critical patent/JP2009529544A/ja
Publication of JP2009529544A5 publication Critical patent/JP2009529544A5/ja
Application granted granted Critical
Publication of JP5419468B2 publication Critical patent/JP5419468B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008558611A 2006-03-16 2007-03-16 Ｉａｐのｂｉｒドメインに結合する化合物 Expired - Fee Related JP5419468B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78252306P 2006-03-16 2006-03-16
US60/782,523 2006-03-16
US87699406P 2006-12-26 2006-12-26
US60/876,994 2006-12-26
PCT/CA2007/000428 WO2007104162A1 (en) 2006-03-16 2007-03-16 Iap bir domain binding compounds

Publications (3)

Publication Number Publication Date
JP2009529544A JP2009529544A (ja) 2009-08-20
JP2009529544A5 true JP2009529544A5 (https=) 2010-04-30
JP5419468B2 JP5419468B2 (ja) 2014-02-19

Family

ID=38509005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558611A Expired - Fee Related JP5419468B2 (ja) 2006-03-16 2007-03-16 Ｉａｐのｂｉｒドメインに結合する化合物

Country Status (15)

Country Link
US (5) US7579320B2 (https=)
EP (1) EP2004600A4 (https=)
JP (1) JP5419468B2 (https=)
KR (1) KR101446907B1 (https=)
AU (1) AU2007224932B2 (https=)
BR (1) BRPI0709610A2 (https=)
CA (1) CA2581960C (https=)
IL (1) IL193951A (https=)
MX (1) MX2008011837A (https=)
NO (1) NO20083868L (https=)
NZ (1) NZ571577A (https=)
PH (1) PH12014502420B1 (https=)
SG (1) SG170739A1 (https=)
TW (2) TWI504597B (https=)
WO (1) WO2007104162A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US7772177B2 (en) * 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007106192A2 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0708942A2 (pt) * 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR20090041391A (ko) * 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
JP5454943B2 (ja) * 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
PE20130150A1 (es) * 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
MX2010011288A (es) 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009155709A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CN102171209A (zh) * 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
WO2010015090A1 (en) * 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US20110177060A1 (en) * 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2784076A1 (en) * 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
WO2012052758A1 (en) * 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2020112855A1 (en) * 2018-11-29 2020-06-04 Reform Biologics, Llc Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
CA2916970A1 (en) * 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
AU2018308116A1 (en) * 2017-07-25 2020-02-13 Hepagene Therapeutics (HK) Limited Dimeric peptide inhibitors of apoptosis proteins
CN109407133B (zh) * 2017-08-18 2023-09-22 南京中硼联康医疗科技有限公司 生物剂量计及具有其的中子捕获治疗系统
JP2021523092A (ja) * 2018-03-21 2021-09-02 ピラマル・ファーマ・リミテッドＰｉｒａｍａｌ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ アルファ−（ジアリールメチル）アルキルアミンの改良された不斉合成
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
CN113677399B (zh) * 2019-04-05 2024-10-11 和博医药有限公司 凋亡蛋白抑制剂的二价拮抗剂
WO2020223403A1 (en) * 2019-04-29 2020-11-05 The Regents Of The University Of California Anticancer smac derivatives
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
US11814367B2 (en) 2021-03-15 2023-11-14 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof
JP7260725B1 (ja) * 2021-12-27 2023-04-18 株式会社トクヤマ ペプチド製造方法、保護基の除去方法、及び除去剤
WO2023127331A1 (ja) * 2021-12-27 2023-07-06 株式会社トクヤマ ペプチド製造方法、保護基の除去方法、除去剤、及びベンジル化合物

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US93428A (en) * 1869-08-10 Improvement in spurs for excelsior-machines
US180828A (en) * 1876-08-08 Improvement in horse-powers
US207525A (en) * 1878-08-27 Improvement in car-coupling draw-bars
US89896A (en) * 1869-05-11 Improvement in bee-hive
US194741A (en) * 1877-08-28 Improvement in circular looms
US219140A (en) * 1879-09-02 Improvement in the art of ornamenting metallic foils
US69812A (en) * 1867-10-15 Improved refrigerator
US93429A (en) * 1869-08-10 Improvement in flasks for vulcanizing rubber plates for setting teeth
US25347A (en) * 1859-09-06 Improvement
US258581A (en) * 1882-05-30 husset
US211627A (en) * 1879-01-28 Improvement in perforating-stamps
US32437A (en) * 1861-05-28 Improvement in steam-plows
JPH0680077B2 (ja) 1985-02-08 1994-10-12 サントリー株式会社 プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物
JPH04208299A (ja) 1990-11-30 1992-07-29 Ajinomoto Co Inc プロリルエンドペプチターゼ阻害ペプチド
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AUPN727595A0 (en) * 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
JP4208299B2 (ja) 1998-08-19 2009-01-14 東レ株式会社 金属板貼合わせ成形加工用ポリエステルフィルム
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
AU2001293189A1 (en) 2000-09-29 2002-04-08 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
EP1392317A4 (en) * 2001-05-16 2005-10-19 Antexpharma Inc SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
CA2449168A1 (en) 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
ES2278928T3 (es) * 2001-06-19 2007-08-16 Altana Pharma Ag Inhibidores de triptasa.
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
FR2844271A1 (fr) * 2002-09-09 2004-03-12 Oreal Derives bis-paraphenylenediamine a groupement pyrrolidinyle et utilisation de ces derives pour la coloration de fibres keratiniques
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
WO2005049853A2 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
KR20060126548A (ko) 2004-02-05 2006-12-07 노파르티스 아게 (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물
CN1926118A (zh) * 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
WO2005094818A1 (en) 2004-03-23 2005-10-13 Genentech, Inc. Azabicyclo-octane inhibitors of iap
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
BRPI0511350A (pt) 2004-07-02 2007-12-04 Genentech Inc composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
EP1888619B1 (en) 2005-05-25 2013-04-17 2cureX ApS Compounds modifying apoptosis
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2007021825A2 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007106192A2 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2007075525A2 (en) 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0708942A2 (pt) 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
KR20090041391A (ko) 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002166A1 (es) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
KR20090082221A (ko) 2006-10-19 2009-07-29 노파르티스 아게 유기 화합물
CN101541325A (zh) 2006-11-28 2009-09-23 诺瓦提斯公司 Iap抑制剂用于治疗急性髓性白血病的用途
KR20090087094A (ko) 2006-11-28 2009-08-14 노파르티스 아게 Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물
ATE542798T1 (de) 2006-12-07 2012-02-15 Novartis Ag Organische verbindungen
US8063218B2 (en) 2006-12-19 2011-11-22 Genentech, Inc. Imidazopyridine inhibitors of IAP
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
WO2008144925A1 (en) 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers

Similar Documents

Publication Publication Date Title
JP2009529544A5 (https=)
JP2009512719A5 (https=)
JP2023062187A (ja) 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ
RU2483061C2 (ru) Тетрагидропиранохроменовые ингибиторы гамма-секретазы
JP2009537461A5 (https=)
JP6002040B2 (ja) 低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物
EP0622076B1 (en) Inhibitor for restenosis after percutaneous coronary arterioplasty
WO2008124384A2 (en) Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
KR20210002015A (ko) Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
EP2512469A1 (en) 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma
KR20210079313A (ko) 암 치료에서 면역 조절을 위한 조합
US20110281814A1 (en) Methods and compositions for treating breast cancer
JP2024523126A (ja) Ｎｒｈ、ｎａｒｈ、及びそれらの還元誘導体を用いた免疫関連障害、腎障害、肝障害、溶血性障害、及び酸化的ストレス関連障害の処置
EP1968589A2 (en) Combinations comprising sorafenib and interferon for the treatment of cancer
CA2789750A1 (en) Ghrelin receptor agonist for treatment of cachexia
RU2016123855A (ru) Ингибиторы протеинкиназы
JP2016537367A5 (https=)
EP3888647B1 (en) Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as combination drug
AU2022291381B2 (en) Combination mcl-1 inhibitors with anti-cancer agents
EP2780011B1 (en) Combination therapy for ovarian cancer
JP7468829B2 (ja) 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
AU2009221720A1 (en) Improved anticancer treatments
JP2026502179A (ja) 置換３，７－ジヒドロ－１ｈ－プリン－２，６－ジオンおよびその使用
BG107806A (bg) Състав, включващ камптотецинови и стилбенови производни, за лечение на рак